Breast cancer from oral and transdermal estradiol: a cohort study of Finnish women.
Evaluation of: Lyytinen H, Pukkala E, Ylikorkala O: Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet. Gynecol. 108(6), 1354-1360 (2006) [1] . A cohort study of 84,729 Finnish women over the age of 50 years who used oral or transdermal estradiol for at least 6 months, followed for the incidence of breast cancer using a national cancer registry. The study was conducted to evaluate whether the risk of breast cancer with estrogen-only therapy varies by dose, constituents or route of administration. A total of 2171 women developed breast cancer, with no increased risk observed for less than 5 years of use, and some risk for greater than 5 years of use for both oral and transdermal routes of administration.
Wong
Tanping
T
Division of General Internal Medicine, New York University School of Medicine, VA New York Harbor HCS, 423 E. 23rd Street - 15N, New York, NY 10010, USA. nirav.shah@med.nyu.edu.
Shah
Nirav R
NR